Diana Bilton

Diana Bilton

Auto-generated profile, based on publicly available information

Diana Bilton

Adult Cystic Fibrosis Centre, Royal Brompton Hospital, London, United Kingdom

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Journal of Cystic Fibrosis
Verified
Journal Article
Open access
NVNataliya Volkova
Nataliya Volkova
KMKristin Moy
Kristin Moy
JEJennifer Evans
Jennifer Evans
DCDaniel Campbell
Daniel Campbell
STSimon Tian
Simon Tian
DBDiana Bilton
Diana Bilton
Ivacaftor is the first in a class of drugs, CFTR modulators, that target the underlying defect in cystic fibrosis (CF). This long-term observational safety study evaluated CF disease progression in patients treated with ivacaftor in a real-world setting for up to 5 years. Data from existing US and UK CF patient registries were used to assess longitudinal patterns in lung function, nutritional status, pulmonary exacerbations and hospitalizations, CF-related diabetes (CFRD), and Pseudomonas aeruginosa in ivacaftor-treated vs untreated comparator cohorts matched by age, sex, and disease severity. US analyses included 635 ivacaftor-treated patients and 1874 comparators followed for 5 years from year 1 of market availability (2012-2016). Evaluation of outcome patterns from pretreatment baseline (2011) through year 5 (2016), showed that relative to comparators, ivacaftor-treated patients had better preserved lung function (mean change in percent predicted FEV1, -0.7 percentage points with ivacaftor vs -8.3 percentage points in comparators) and improved nutritional status (mean body mass index change +2.4 kg/m2 with ivacaftor vs +1.6 kg/m2 in comparators). US patients treated with ivacaftor had significantly lower frequencies of exacerbations and hospitalizations in each of the 5 years of follow-up relative to pretreatment baseline and comparators. Favorable trends in CFRD and P. aeruginosa prevalence were also observed. Findings from the smaller UK registry were directionally similar to and consistent with US findings. This observational study represents the largest longitudinal analysis of patients treated with ivacaftor in a real-world setting. The findings support disease modification by CFTR modulation with ivacaftor.

1 June 2011 in Journal of Cystic Fibrosis
Verified
Journal Article
Closed access
DBD. Bilton
D. Bilton
GCG. Canny
G. Canny
SCS. Conway
S. Conway
SDS. Dumcius
S. Dumcius
LHL. Hjelte
L. Hjelte
KBK. De Boeck
K. De Boeck

8 April 2011 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
DBD. Bilton
D. Bilton
PRP. Robinson
P. Robinson
PCP. Cooper
P. Cooper
CGC.G. Gallagher
C.G. Gallagher
JKJ. Kolbe
J. Kolbe
BCB. Charlton
B. Charlton
This international phase III study of inhaled dry powder mannitol was a randomised, double-blind, 26-week study, followed by a further 26-week, open-label (OL) extension. 324 cystic fibrosis (CF) patients were randomised, in a 3:2 ratio, to mannitol (400 mgb.i.d.) and control groups. The primary efficacy end-point was to determine the change in forced expiratory volume in 1 s (FEV1) over the double-blind phase. Secondary end-points included changes in forced vital capacity and pulmonary exacerbations.A significant improvement in FEV1was seen over 26 weeks (p<0.001) and was apparent by 6 weeks, irrespective of concomitant recombinant human deoxyribonuclease (rhDNase) use. At 26 weeks, there was a significant improvement in FEV1of 92.9 mL for subjects receiving mannitol compared with controls (change from baseline 118.9 mL (6.5%)versus26.0 mL (2.4%); p<0.001). Improvements in FEV1were maintained up to 52 weeks in the OL part of the study. There was a 35.4% reduction in the incidence of having an exacerbation on mannitol (p=0.045).The incidence of adverse events (AEs) was similar in both groups, although treatment-related AEs were higher in the mannitol compared with the control group. The most common mannitol-related AEs were cough, haemoptysis and pharyngolaryngeal pain.Mannitol showed sustained, clinically meaningful benefit in airway function in CF, irrespective of concomitant rhDNase use. Mannitol appears to have an acceptable safety profile for patients with CF.

1 July 2013 in Chest
Verified
Journal Article
Closed access
DBDiana Bilton
Diana Bilton
EDEvangelia Daviskas
Evangelia Daviskas
SASandra Anderson
Sandra Anderson
JKJohn Kolbe
John Kolbe
GKGregory King
Gregory King
BCBrett Charlton
Brett Charlton

4 April 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MTMireille B Toledano
Mireille B Toledano
SMS K Mukherjee
S K Mukherjee
JHJ Howell
J Howell
DWD Westaby
D Westaby
SKS A Khan
S A Khan
NSN J Simmonds
N J Simmonds
Cystic fibrosis associated liver disease (CFLD) is the third largest cause of mortality in CF. Our aim was to define the burden of CFLD in the UK using national registry data and identify risk factors for progressive disease. A longitudinal population-based cohort study was conducted. Cases were defined as all patients with CFLD identified from the UK CF Registry, 2008–2013 (n = 3417). Denominator data were derived from the entire UK CF Registry. The burden of CFLD was characterised. Regression analysis was undertaken to identify risk factors for cirrhosis and progression. Prevalence of CFLD increased from 203.4 to 228.3 per 1000 patients during 2008–2013. Mortality in CF patients with CFLD was more than double those without; cirrhotic patients had higher all-cause mortality (HR 1.54, 95% CI 1.09 to 2.18, p = 0.015). Median recorded age of cirrhosis diagnosis was 19 (range 5–53) years. Male sex, Pseudomonas airway infection and CF related diabetes were independent risk factors for cirrhosis. Ursodeoxycholic acid use was associated with prolonged survival in patients without cirrhosis. This study highlights an important changing disease burden of CFLD. The prevalence is slowly increasing and, importantly, the disease is not just being diagnosed in childhood. Although the role of ursodeoxycholic acid remains controversial, this study identified a positive association with survival.

1 November 2008 in Current Opinion in Pulmonary Medicine
Verified
Journal Article
Closed access
DBDiana Bilton
Diana Bilton
There is growing awareness in both adult and paediatric respiratory clinics regarding the importance of non-cystic fibrosis bronchiectasis. There has been debate regarding the requirement for investigations to establish an underlying cause of bronchiectasis. Furthermore, there has been growing interest in establishing the role of bacteria in disease progression. Post-infection is no longer the most common cause of bronchiectasis in developed countries in children or adults and the importance of identifying immunodeficiency has been underlined. Nontuberculous mycobacteria are recognized as both causing and complicating non-cystic fibrosis bronchiectasis. It has been suggested that infection with Pseudomonas aeruginosa may confer a worse prognosis compared with other pathogens but recent publications produce conflicting views. There is increasing recognition that patients with non-cystic fibrosis bronchiectasis do not necessarily respond to cystic fibrosis treatment regimens in the same way as patients with cystic fibrosis regimens. Non-cystic fibrosis bronchiectasis can be approached in a systematic fashion to establish the underlying cause and develop treatment strategies.